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Sarcopenia andmuscular dystrophy are both characterized by the loss of muscle mass and increased
intramuscular fibrosis. The two conditions also share several pathophysiological mechanisms,
including mitochondrial dysfunction, increased apoptosis, abnormal regulation of autophagy,
decline in satellite cell function, increased generation of reactive oxygen species, and alterations of
signaling and stress response pathways. Basic science researchers and clinicians working in the areas
of sarcopenia and muscular dystrophy in human and animal models contributed to this research
topic (Alway et al., 2014; Calvani et al., 2014; Cesari et al., 2014; De Palma et al., 2014; Gattazzo et al.,
2014; Harris-Love et al., 2014; Hepple, 2014; Holland et al., 2014; Holmberg et al., 2014; Jungbluth
and Gautel, 2014; Kern et al., 2014; La Rovere et al., 2014; Lim et al., 2014; Malatesta et al., 2014;
Marzetti et al., 2014; Merlini et al., 2014; Palmio and Udd, 2014; Pozzobon et al., 2014; Raz and Raz,
2014; Rudolf et al., 2014; Sabatelli et al., 2014; Sakuma et al., 2014; Sanchis-Gomar et al., 2014; Tamaki
et al., 2014; Toni et al., 2014; Zulian et al., 2014; Krause, 2015). The aim of this cross-fertilization was
to accelerate our understanding of themechanisms involved in aging and dystrophic sarcopenia and
to explore the therapeutic potential of various intervention modalities.
Since its first “official” appreciation back in 1989 (Rosenberg, 1989), sarcopenia has attracted
great research interest. The intimate relationship between muscle loss and advancing age, evident
across multiple species, has led researchers to consider sarcopenia as a paradigm for exploring
the aging process as a whole. Sarcopenia is indeed envisioned as a biomarker of aging, able to
distinguish, at the clinical level, biological from chronological age (Fisher, 2004). This view is
supported by the association reported between sarcopenia and the length of telomeres in peripheral
blood mononuclear cells (PBMCs), a popular biological marker of senescence (Marzetti et al.,
2014). This relationship seemed to be driven mainly by the muscle mass, which suggests the
existence of a common pathogenic basis for muscle atrophy and telomere attrition. No significant
association was found between PBMC telomere length and muscle strength or function parameters,
pointing at distinct pathogenic mechanisms underlying the quantitative and qualitative dimensions
of sarcopenia.
Decreased number and impaired function of satellite cells, the major stem cell population
responsible for skeletal muscle regeneration during adulthood, are considered to be major the
mechanisms contributing to sarcopenia (Chakkalakal and Brack, 2012). Along with changes in
systemic factors and the environmental cues provided by satellite cells, oxidative stress that char-
acterizes the aged muscle contributes to impairing satellite cells responses to exercise, disuse, and
rehabilitation. Some nutritional intervention may improve satellite cell function in aged muscles;
however, the effect of nutraceuticals on satellite cell function in the context of sarcopenia is not
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yet well established. Alway et al. (2014) provided an overview on
the contribution of satellite cell dysfunction to sarcopenia. The
authors also reviewed data from preclinical studies showing that
the administration of specific nutraceuticals (resveratrol, green tea
catechins, and β-hydroxy-β-methylbutyrate) may improve satel-
lite cell function, thereby mitigating sarcopenia and promoting
muscle recovery after disuse.
Most studies aimed at testing potential therapeutic approaches
targeting satellite cells in muscle diseases have been conducted
in small mammalian models. Though, our knowledge of muscle
regeneration in large animal models, such as dogs, remains rela-
tively limited. La Rovere et al. (2014) investigated the myogenic
potential of satellite cells isolated from somite- and presomite-
derived muscles of young and aged dogs, as well as from Golden
Retrievers affected by muscular dystrophy. Satellite cells obtained
from the two canine sources showed different proliferation and
differentiation rates. Indeed, those isolated from presomitic-
derived muscle showed higher telomerase activity and stronger
stem cell potential, whereas satellite cells obtained from somitic-
derivedmuscle expressed early and late myogenic markers, result-
ing in more efficient cell differentiation. Interestingly, expression
profiling of muscle-specific miRNAs revealed a unique epigenetic
signature inGoldenRetrievermuscular dystrophy, suggesting that
miR-206 might represent a potential target for therapy.
Satellite cell dysfunction is involved in collagen VI-related
myopathies. Collagen VI is an extracellular matrix protein, essen-
tial formuscle homeostasis (Bonaldo et al., 1998).Mutations in the
gene encoding for collagen VI cause different forms of inherited
myopathies and congenital muscular dystrophies. Studies carried
out during the last decade in collagen VI null mice provided
new insights into the pathomolecular mechanisms of collagen
VI-related myopathies, leading to pilot clinical trials in human
subjects. In addition to mitochondrial dysfunction and defective
autophagy, lack of collagen VI affects muscle regeneration and
self-renewal of satellite cells. Gattazzo et al. (2014) investigated the
effects of cyclosporinA onmuscle regeneration in collagenVI null
mice under basal conditions and after cardiotoxin-inducedmuscle
injury. The authors provided evidence that cyclosporin A influ-
enced satellite cell activity and triggered the formation of regen-
erating fibers. Data obtained on collagen VI null mice showed
that, under appropriate administration regimens, cyclosporin A
was capable of stimulating myogenesis and aiding in regeneration
of injured muscles.
Muscular dystrophies perturb regenerative processes, which
causes the premature exhaustion of the satellite cell reservoir due
to continuous cycles of degeneration/regeneration (Decary et al.,
2000). Pozzobon et al. (2014) provided an overview on the use of
fetal-derived stem cells as a new therapeutic approach in muscle
diseases. The authors highlight that cells of fetal origin (e.g., cord
blood, placenta, amniotic fluid) can be easily obtained without
ethical concern and expanded and differentiated in culture; such
cells also possess immune-modulatory properties. They also high-
light that different types of fetal stem cells of human and mouse
origin display myogenic differentiation capabilities.
In recent years, mitochondrial dysfunction has received
increasing attention as a possible target for interventions against
sarcopenia (Marzetti et al., 2013). Mitochondria are indeed
located at the cross-roads of several vital pathways, including
energy production, redox homeostasis, cellular quality control,
and cell death/survival signaling. As pointed out by Hepple
(2014), however, the degree by which advancing age impacts
muscular mitochondrial function is probably milder than previ-
ously thought. In fact, the procedures for mechanical isolation of
mitochondria can themselves induce alterations in the intrinsic
function of the organelle. In contrast, assays performed using
permeabilized muscle fibers may provide more reliable results
because mitochondria are not subjected to artificial mechani-
cal damage and are analyzed within their normal architectural
organization in the myofiber. Based on the most recent evi-
dence, Hepple (2014) proposed that dysfunctional mitochon-
drial autophagy and an increased propensity toward permeability
transition may represent relevant therapeutic targets for anti-
sarcopenic interventions.
Mitochondrial dysfunction plays a major role in the patho-
genesis of collagen VI-related myopathies through a short cir-
cuit caused by inappropriate opening of the permeability transi-
tion pore. The latter is a high-conductance channel that causes
a shortage of ATP production (Bernardi and Bonaldo, 2013).
Melanocytes obtained from skin biopsies do not produce col-
lagen VI, yet they bind collagen VI at the cell surface, sug-
gesting that this protein plays a trophic role in healthy muscle
(Zulian et al., 2014).Mitochondria ofmelanocytes of patients with
collagen VI-related myopathies display increased size, reduced
matrix density, and disrupted cristae, indicative of mitochon-
drial functional impairment. After inhibition of the F1F0-ATP
synthase with oligomycin, mitochondria underwent anomalous
depolarization and showed decreased respiratory reserve capacity.
The non-immunosuppressive cyclophilin inhibitor NIM811 pre-
ventedmitochondrial depolarization in response to oligomycin in
melanocytes from myopathic patients.
Well-functioning autophagy is fundamental for organismal
health and longevity (Bonaldo and Sandri, 2013). Excessive activa-
tion of autophagy-dependent degradation contributes to muscle
atrophy and cachexia, whereas its suppression results in accu-
mulation of protein aggregates and abnormal organelles, leading
to myofiber degeneration. Lim et al. (2014) provide a detailed
overview of the current knowledge of Pompe disease with a dis-
cussion on recent insights into the molecular mechanisms and
novel perspectives for therapy. Pompe disease is a lysosomal stor-
age disorder causing progressive accumulation of glycogen-filled
lysosomes in several tissues, with cardiac and skeletal muscles
being themost severely affected. Lysosomal enlargement was long
considered to be the major mechanism causing muscle damage
in Pompe disease. However, accumulating evidence indicates that
dysfunctional autophagy and accelerated production of lipofuscin
inclusions are deeply involved in the onset of muscle damage
and interfere with acid alpha-glucosidase delivery during therapy.
Several novel therapeutic approaches have recently been tested in
mouse models of Pompe disease, including lysosomal exocytosis
and manipulation of autophagy.
Along similar lines, De Palma et al. (2014) review recent find-
ings showing that dysfunctional autophagy plays a pathogenic
role in muscular dystrophies. The authors highlight the clinical
relevance of the recent findings on the role of autophagy and its
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regulatory signaling pathways in Duchenne muscular dystrophy.
They also discuss how modulating autophagy may represent a
promising strategy for therapeutic interventions aimed at coun-
teracting muscle wasting in muscular dystrophies.
Jungbluth and Gautel (2014) provided an overview of the
clinical, histopathological, and genetic aspects of centronuclear
myopathies in the context of key pathogenic mechanisms. Mod-
els to study and rescue the affected cellular pathways are now
available in yeast, Caenorhabditis elegans, Drosophila, zebrafish,
mouse, and dog. Defects in membrane trafficking have emerged
as a key pathogenic mechanism, in particular aberrant T-
tubule formation, abnormalities of triadic assembly, and dis-
turbance of the excitation–contraction machinery. Abnormal
autophagy has recently been indicated as another important
pathogenic mechanism in different genetic forms of centronu-
clear myopathies that may be potentially amenable to therapeutic
interventions.
The complexity of the cellular mechanisms underlying the
pathophysiology of sarcopenia may be deciphered through the
use of well-characterized muscle disorders that recapitulate, at
least in part, the phenotype of pathological muscle aging. Late-
onset autosomal dominant oculopharyngeal muscular dystrophy
(OPMD)maywell serve that purpose (Raz andRaz, 2014). OPMD
is a rare monogenic disorder caused by an expansion muta-
tion in the gene encoding poly-adenylate RNA binding protein1
(PABPN1). Symptoms begin in midlife and progress with advanc-
ing age. Ocular and pharyngealmuscles are thosemost commonly
affected at the disease onset. As the disorder progresses, other
muscles, especially of the lower limbs, become impaired. The
molecular signatures of OPMD muscles show remarkable over-
lap with sarcopenia. For instance, the accumulation of insoluble
protein aggregates, a hallmark of OPMD, has also been observed
in aged muscles and attributed to a dysfunctional ubiquitin-
proteasome system and defective autophagy. It is worth noting
that mitochondrial dysfunction contributes to muscle degenera-
tion in bothOPMDand sarcopenia, further supporting the propo-
sition that OPMD may represent a model for accelerated muscle
aging.
Sabatelli et al. (2014) observed aggresome-autophagy involve-
ment in a sarcopenic patient with rigid spine syndrome and
a p.C150R mutation in the four-and-half LIM domain protein
1 gene (FHL1). The 34-year-old wheelchair-bound woman had
an early and progressive rigidity of the cervical spine, marked
diffuse muscle wasting, weakness, prominent contractures, and
severe respiratory insufficiency. According to a BMI of 17.1, she
was underweight; however, her body composition, estimated by
DXA, revealed that she was sarcopenic/obese with a marked
reduction of lean body mass and a total body fat of 44%. Muscle
biopsy showed multiprotein aggregates throughout the cytoplasm
and around myonuclei with aggresome/autophagy features and
nuclear degradation.
Other pathophysiologic mechanisms of aging and dystrophic
sarcopenia were explored by the seven following contributions.
The possibility of considering muscular dystrophy a model
of accelerated sarcopenia is supported by the observation that
the two conditions exhibit marked defects of the autophagy-
lysosome system, likely as a consequence of dysfunctional
Akt/mTOR/p70S6K pathway and disruption of serum response
factor (SRF)-dependent signaling (Sakuma et al., 2014).
Upregulation ofmyostatin signaling is also commonly observed in
both muscular dystrophy and sarcopenia. Remarkably, preclinical
studies have shown that pharmacological downregulation of
myostatin signaling attenuates the pathological phenotype in
sarcopenic rodents and several mouse models of muscular
dystrophy.
A large number of studies in mdx mice, the rodent model of
Duchennemuscular dystrophy, led to the concept that aging exac-
erbates the dystrophic phenotype of dystrophin-deficient mice.
Holland et al. (2014) outline recent data on the age-dependent
changes of the senescentmdxmuscle proteome and discuss these
findings in comparison with the proteomic profile of sarcopenic
muscle. These comparative muscle proteomics not only con-
firmed similar perturbations in a number of biochemical pro-
cesses, but also revealed striking similarities in cellular stress
responses between the two conditions.
Muscle denervation is a hallmark of sarcopenia and muscular
dystrophy (Deschenes, 2011).During the development of sarcope-
nia and muscular dystrophy, neuromuscular junctions (NMJs)
deteriorate and display altered molecular features. Rudolf et al.
(2014) provided an overview of NMJ alterations observed in
sarcopenic and dystrophic muscles. The authors also reviewed
the current knowledge on the molecular mechanisms underlying
NMJ degeneration during aging and in the context of muscular
dystrophies. As pointed out byRudolf et al. (2014), the observation
that physical exercise can reverse NMJ abnormalities in the aged
muscle opens new venues for the design of treatments targeting
the NMJ to rescue muscle mass in sarcopenia and muscular
dystrophies.
It is a common notion that the loss of muscle mass and strength
follows different trajectories over time, with steeper declines in
strength relative to mass (Goodpaster et al., 2006). Findings
from Tamaki et al. (2014) provide a convincing explanation for
such a phenomenon. The authors elegantly show that qualita-
tive alterations of the peripheral motor system (i.e., reduction
of shortening and relaxing velocity of twitch, impaired motor
unit recruitment at high stimulation frequencies, and early NMJ
fatigability) occur well before the appearance of the sarcopenic
phenotype inmiddle-aged rats. Interestingly, significant decreases
in muscle shortening and relaxing velocity during serial twitch
contractions, accompanied by type-IIb to type-I fiber shift, were
detected in middle-aged rats in the absence of muscle atrophy.
These changes may be prodromic to the well-known prefer-
ential loss of fast-twitch fibers that characterize the sarcopenic
muscle.
Malatesta et al. (2014) provide convincing arguments in favor
of a partly common physiopathologic substratum for myotonic
dystrophy (DM) and sarcopenia. DM is an autosomal dom-
inant disorder that originates from nucleotide expansions. At
the histological level, DM and sarcopenia are characterized by
myofiber atrophy, fiber size variability, and centrally located
nuclei. The two conditions also share a number of ultrastructural
and functional features, including nuclear rearrangement of the
RNP-containing domains, likely due to defects in the machin-
ery responsible for pre-mRNA transcription and maturation,
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and satellite cell dysfunction. Interestingly, both in DM and
sarcopenia, muscleblind-like 1 (MBNL1), an alternative-splicing
factor, undergoes intranuclear relocation and accumulation,
which contributes to hampering the functionality of the whole
splicingmachinery. This, in turn, reduces nuclearmetabolic activ-
ity, therefore impairing protein synthesis. Defects in pre-mRNA
post-transcriptional pathways are believed to account for the
aging-reminiscent muscle phenotype of DM patients and suggest
that muscle wasting in DM and sarcopenia may originate from
similar mechanisms.
Within the intricate network of mechanisms underlying the
pathophysiology of muscular dystrophies, miRNAs certainly play
a role (Eisenberg et al., 2009). miRNAs are widespread regulators
of gene expression, but little is known about their potential roles
in congenital muscular dystrophies. MDC1A is a severe form of
congenital muscular dystrophy caused by mutations of the gene
encoding laminin α2, a key component of the basal lamina in
muscle endomysium. To gain insight into the pathophysiologi-
cal roles of miRNAs associated with MDC1A Holmberg et al.
(2014) analyzed a number of miRNAs in the skeletal muscles
of laminin α2 chain-deficient mice and found that expression
of muscle-specific miR-1, miR-133a, and miR-206 is deregu-
lated in these muscles. They also demonstrate that plasma levels
of muscle-specific miRNAs are elevated in laminin α2 chain-
deficient mice and are partially normalized in response to pro-
teasome inhibition. These findings indicate that muscle-specific
miRNAs are deregulated inMDC1A and suggest that their plasma
levels may represent promising biomarkers for evaluating disease
progression.
Several different and partly overlapping muscle degeneration
pathways are involved in another group of myopathies character-
ized by the presence of inclusions, such as hereditary inclusion
bodymyopathy (IBM), IBMwith Paget’s disease of bone and fron-
totemporal dementia (IBMPFD), and GNE myopathy (Krause,
2015). Mutations in VCP/p97 responsible for IBMPFD are asso-
ciated with defective myosin assembly, deregulation of major
protein degradation pathways, reduced regeneration capability,
and impaired mitochondrial quality control. However, a plethora
of mechanisms underlying disease onset in hereditary IBMs
remains to be elucidated at the molecular and pathophysiological
level.
The five following contributions explored clinical aspects and
evaluation methods. Harris-Love et al. (2014) provide prelim-
inary data about the use of real-time augmented feedback for
quantitative ultrasound imaging. The authors suggest that a better
understanding of both the promise of quantitative ultrasound as
an assessment tool for muscle disorders and the known threats to
measurement validity may foster greater adoption of this imag-
ing modality in the management of muscular dystrophy and
sarcopenia.
Since a distinction between normal age-related weakening of
muscle strength and clinically significant muscle disease is not
always obvious, the correct diagnosis is easily missed. Palmio and
Udd (2014) performed magnetic resonance imaging in patients
with three types of late onset limb girdle muscular dystrophy,
highlighting differences as comparedwith a healthy aged-matched
control. Therefore, muscle imaging should be considered as
a means to distinguish between aging sarcopenia and muscle
disease.
The quantitative and qualitative domains of sarcopenia con-
cur to the development of the clinical phenotype, dominated by
muscle weakness, poor balance, and slow gait speed. This clinical
picture shows substantial overlap with that of physical frailty
(Landi et al., 2015). The latter is a geriatric syndrome characterized
by reduced homeostatic reserves, which exposes the individual
at increased risk of negative health-related events in response to
internal and/or external stressors. Based on the conceptual model
proposed by Cesari et al. (2014), physical function represents the
shared core of sarcopenia and physical frailty. Accordingly, the
two conditions may be combined into one clinical entity. Such
an operationalization provides researchers and clinicians with
an objective, standardized, and clinically relevant condition that
can easily be translated to the clinical arena. The recognition of
skeletal muscle as the biological substrate of physical frailty is
also functional to the design of new preventive and therapeutic
interventions.
Merlini et al. (2014) evaluated the presence of sarcopenia
and obesity in a cohort of 14 adult patients with muscular dys-
trophy. As determined by DXA, all of the patients resulted in
sarcopenic based on appendicular lean mass index and obese
according to the percentage of body fat. Skeletal muscle mass
was markedly reduced in all patients and correlated with residual
muscle strength, determined by hand-held dynamometry, and
physical performance, as assessed by gait speed and respiratory
function.
Toni et al. (2014) evaluated the nutritional status in seven
patients with collagen type VI myopathies. As determined by
DXA, all patients showed altered body composition. Specifically,
all patients were sarcopenic, and all but one sarcopenic/obese.
The authors found a negative correlation between basal energy
expenditure per kilogram of fat free mass and the severity of the
disease, which may be indicative of loss of muscular energetic
efficiency.
Finally, treatments targeting sarcopenia with electrical stimu-
lation (ES), nutritional intervention, and physical exercise were
discussed.
The possibility of counteracting the age-related muscle decline
was assessed through electrical stimulation (ES) of the thigh
muscles (Kern et al., 2014). The effect of 9 weeks of training in
healthy seniors was analyzed at functional, structural, and molec-
ular levels. ES was able to improve muscle torque and functional
performance, and increased the diameter of fast muscle fibers. At
themolecular level, ES induced upregulation of IGF-1, the expres-
sion of markers of satellite cell activation, and downregulation
of MuRF-1, a muscle specific atrophy-related gene. Conversely,
autophagy was unaffected by ES.
The origins of sarcopenia are multifactorial and only partly
understood. However, protein-energy malnutrition is a well-
known cause of muscle loss in advanced age (Calvani et al.,
2013). Noticeably, failure to meet an adequate dietary intake is
also involved in the pathogenesis of osteoporosis. The coexistence
of sarcopenia and osteoporosis greatly increases the risk of falls
and fractures, respectively. The negative outcomes associated with
geriatric fractures, especially of the hip, call for the development of
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novel strategies to reduce the incidence of new events and improve
clinical and functional outcomes once the fracture has occurred.
To this end, Calvani et al. (2014) explored the association between
dietary intake and sarcopenia in a sample of older hip-fractured
patients. As predicted, low dietary intake was found to be associ-
ated with reduced muscle mass at the time of hip fracture. This
evidence provides the foundation for the design of nutritional
interventions targeting the skeletal muscle to achieve therapeutic
gain in this especially vulnerable patient population.
Besides the optimization of nutrition, engagement in reg-
ular physical activity is widely recognized as an effective
measure for preventing and treating sarcopenia (Landi et al.,
2014). As illustrated by Sanchis-Gomar et al. (2014), physi-
cal exercise is indeed able to modulate most of the pathways
believed to underlie the pathogenesis of sarcopenia (e.g., cel-
lular quality control mechanisms, sestrins, mitochondrial bio-
genesis, and oxidative stress). The authors also indicate a num-
ber of potential biological targets for drug development against
sarcopenia. These include the age-dependent decrease in cellu-
lar NAD+ pool, the p16INK4a tumor suppressor, the FGF21-
PGC-1α-irisin axis, the myostatin/follistatin pathway, and the
IGF-1/Akt/mTOR axis.
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